BIOS podcast

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل four أعوام

المحتوى المقدم من Alix Ventures. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Alix Ventures أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

Squid Game: The Official Podcast

1
Keys and Knives - S3 Ep 1 26:28

منذ 14 يومًا26:28

التشغيل لاحقا

قوائم

إعجاب

احب

26:28

Squid Game is back—and this time, the knives are out. In the thrilling Season 3 premiere, Player 456 is spiraling and a brutal round of hide-and-seek forces players to kill or be killed. Hosts Phil Yu and Kiera Please break down Gi-hun’s descent into vengeance, Guard 011’s daring betrayal of the Game, and the shocking moment players are forced to choose between murdering their friends… or dying. Then, Carlos Juico and Gavin Ruta from the Jumpers Jump podcast join us to unpack their wild theories for the season. Plus, Phil and Kiera face off in a high-stakes round of “Hot Sweet Potato.” SPOILER ALERT! Make sure you watch Squid Game Season 3 Episode 1 before listening on. Play one last time. IG - @SquidGameNetflix X (f.k.a. Twitter) - @SquidGame Check out more from Phil Yu @angryasianman , Kiera Please @kieraplease and the Jumpers Jump podcast Listen to more from Netflix Podcasts . Squid Game: The Official Podcast is produced by Netflix and The Mash-Up Americans.…

BIOS

منزل السلاسل•Feed

BIOS Podcast brings together cutting-edge insights from Life Science industry leaders at the forefront of innovation.

Join us in hearing from Founders, Investors, Professors, & Pharma operating at the intersection of Technology & Biology.

By Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health.

Learn more @ BIOS.community / Alix.vc

__________________________________

Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.

64 حلقات

#Science #Tech #Biology #Entrepreneur #Business #Alix Ventures

BIOS

updated منذ عام واحد

منزل السلاسل•Feed

BIOS Podcast brings together cutting-edge insights from Life Science industry leaders at the forefront of innovation.

Join us in hearing from Founders, Investors, Professors, & Pharma operating at the intersection of Technology & Biology.

By Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health.

Learn more @ BIOS.community / Alix.vc

__________________________________

64 حلقات

#Science #Tech #Biology #Entrepreneur #Business #Alix Ventures

सभी एपिसोड

BIOS

1
63. Immunotherapy Protein Engineering & Entrepreneurship w/ Dane Wittrup - Professor @ MIT 50:00

منذ 1 year50:00

50:00

Professor Dane Wittrup attended the University of New Mexico as an undergraduate, graduating Summa Cum Laude with a Bachelors in Chemical Engineering in June, 1984. Wittrup went on to attend the California Institute of Technology in Pasadena, where he worked with Prof. James Bailey on flow cytometry and segregated modeling of recombinant populations of Saccharomyces cerevisiae. After obtaining his Ph.D. in Chemical Engineering with a minor in Biology in 1988, he spent a brief time working at Amgen before becoming an Assistant Professor of Chemical Engineering at the University of Illinois at Urbana-Champaign in 1989. He moved to the Massachusetts Institute of Technology in September of 1999, where he is now the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, in addition to working with the Koch Institute as the Associate Director for Engineering. w/ Special Guest Host: Jacob Becraft - Co-Founder & CEO @ Strand Therapeutics Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake’s broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
62. Future of Scientific Journalism w/ Holden Thorp - Editor-in-Chief @ Science Journals 50:00

منذ 1 year50:00

50:00

Holden Thorp became Editor-in-Chief of the Science family of journals on 28 October 2019. He came to Science from Washington University, where he was provost from 2013 to 2019 and professor from 2013 to 2023. He is currently a professor at George Washington University and on leave to serve as the Editor-in-Chief at Science. Thorp joined Washington University after spending three decades at the University of North Carolina at Chapel Hill (UNC), where he served as the 10th chancellor from 2008 through 2013. Thorp earned a bachelor of science degree in chemistry from UNC in 1986. He earned a doctorate in chemistry in 1989 at the California Institute of Technology, working with Harry B. Gray on inorganic photochemistry. He completed postdoctoral work at Yale University with Gary W. Brudvig, working on model compounds and reactions for the manganese cluster in the photosynthetic reaction center. He holds an honorary doctor of laws degree from North Carolina Wesleyan College and is a fellow of the American Academy of Arts and Sciences, the National Academy of Inventors, and the American Association for the Advancement of Science. Thorp cofounded Viamet Pharmaceuticals, which developed VIVJOA (oteseconazole), now approved by the FDA and marketed by Mycovia Pharmaceuticals. Thorp is a venture partner at Hatteras Venture Partners, a consultant to Ancora and Urban Impact Advisors, and is on the board of directors of PBS, the College Advising Corps, and Saint Louis University. He serves on the scientific advisory boards of the Yale School of Medicine and the Underwriters’ Laboratories Research Institutes. Thorp is the coauthor, with Buck Goldstein, of two books on higher education: Engines of Innovation: The Entrepreneurial University in the Twenty-First Century and Our Higher Calling: Rebuilding the Partnership Between America and its Colleges and Universities, both from UNC Press. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
61. Frontier of Immunological Engineering w/ Darrell Irvine - Professor @ MIT 50:00

منذ 1 year50:00

50:00

Darrell Irvine obtained an Honors Bachelor’s degree in engineering physics from the University of Pittsburgh. As a National Science Foundation graduate fellow, he then studied Polymer Science at MIT. Following completion of his PhD, he was a Damon Runyon-Walter Winchell postdoctoral fellow in immunology at the Beckman Center for Molecular and Genetic Medicine. He is presently a professor at the Massachusetts Institute of Technology and an investigator of the Howard Hughes Medical Institute. He is also an Associate Director for the Koch Institute and serves on the steering committee of the Ragon Institute of MGH, MIT, and Harvard. Irvine is the founder of Elicio Therapeutics, Strand Therapeutics, and Ankyra Therapeutics. He serves on the Scientific Advisory Boards of the MGH Cancer Center, the University of Toronto Medicine by Design Consortium, Venn Therapeutics, Alloy Therapeutics, Jupiter Therapeutics, Parallel Bio, Surge Therapeutics, and Gensaic Therapeutics. w/ Special Guest Host: Jacob Becraft - Co-Founder & CEO @ Strand Therapeutics Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake’s broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
60. Diagnostic Entrepreneurship w/ Stan Lapidus - Serial Entrepreneur / Former Founder & CEO @ Exact Sciences 50:00

منذ 2 years50:00

50:00

Stan Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards. He’s been founding CEO of three medical diagnostics companies. Two of them have been among the most successful diagnostics startups of all time: Cytyc Corp., which he founded in 1987 and which revolutionized early detection of cervical cancer through its development of the modern Pap test—the ThinPrep. The two ThinPrep prototypes are at the Smithsonian’s American Museum of National History. And, EXACT Sciences, which he founded in 1995, which pioneered non-invasive early detection of colorectal cancer through its Cologuard test. Since its introduction, Cologuard has become the fastest growing test in the history of the diagnostics industry. Stan holds 37 patents, primarily in methods for early detection of cancer. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2014 for his work on the early detection of cancer. He also served as an instructor at MIT from 2001 to 2017. ‍Stan graduated from Cooper Union in New York City with a BS degree in electrical engineering. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
59. Future of ADCs w/ David Epstein - CEO @ Seagen 43:43

منذ 2 years43:43

43:43

David Epstein joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Prior to Seagen, he was executive partner at Flagship Pioneering. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. David holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business. He serves as a member of the board of directors for OPY Acquisition Corp. I and Senti Biosciences, Inc. w/ Special Guest Host: Brian Fiske - Co-Founder & CSO @ Mythic Therapeutics Brian Fiske co-founded Mythic in 2017 & currently serves as Mythic’s Chief Scientific Officer. Prior to Mythic, he was a co-founder and Chief Technology Officer at Ohana Biosciences and a Senior Associate at Flagship Ventures, where he also co-founded KSQ Therapeutics. During his time at Flagship, Brian successfully led R&D teams to key milestones, recruited 25+ FTEs across all levels of seniority, and raised $34M across multiple rounds of financing. In 2016, he was nationally recognized for healthcare entrepreneurship by Forbes 30 under 30. Prior to Flagship, Brian completed his PhD in biology in Matt Vander Heiden’s lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into four clinical programs that include two approved drugs. He holds an AB summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
58. Frontier of Immunology w/ Vijay Kuchroo - Professor @ Harvard 43:43

منذ 2 years43:43

43:43

Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology. Kuchroo came to the United States in 1985, as a Fogarty International Fellow at The National Institutes of Health, Bethesda, MD for one year, before joining the department of pathology at Harvard Medical School, as a research fellow. Later, he joined the Center for Neurologic Diseases at Brigham and Women’s Hospital as a junior faculty member in 1992. He obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research Prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly Lecturer in 2014, and obtained a Nobel Laureate Peter Doherty Lecture/Prize in 2014. Kuchroo has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of internationally recognized pharmaceutical companies including: Biocon, Syngene, Pfizer, Novartis and Glaxo-Smith-Klein (GSK). Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
57. Future of Microfluidics w/ David Weitz - Professor @ Harvard / Core Faculty @ Wyss Institute 43:43

منذ 2 years43:43

43:43

David Weitz is the Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University. Weitz is best known for his work in the areas of diffusing-wave spectroscopy, microrheology, microfluidics, rheology, fluid mechanics, interface and colloid science, colloid chemistry, biophysics, complex fluids, soft condensed matter physics, phase transitions, the study of glass and amorphous solids, liquid crystals, self-assembly, surface-enhanced light scattering, and diffusion-limited aggregation. He received his PhD in superconductivity from Harvard and worked as a research physicist at Exxon Research and Engineering for nearly 18 years, prior to becoming a Professor of Physics at the University of Pennsylvania, before moving to Harvard in 1999. David is a Founder of many startups, including Raindance Technologies, GnuBio, Capsum, HiFiBio, BioMillenia, 1Cell-Bio, NextGen, Calyxia, Transition Bio and DragonDrop Inn. He is a member of the National Academy of Sciences, the National Academy of Engineering and the American Academy of Arts and Sciences. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
56. Future of Gene Editing w/ David Liu - Professor @ Harvard / Vice Chairman @ Broad Institute 43:43

منذ 2 years43:43

43:43

David Liu is the Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University, and a Howard Hughes Medical Institute (HHMI) investigator. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors and prime editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing—the first general method to perform precision gene editing without double-stranded breaks, and a Science 2017 Breakthrough of the Year finalist—as well as prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. These technologies are used by thousands of labs around the world and have enabled the study and potential treatment of many genetic diseases. Four base editing clinical trials are already underway to treat leukemia, hypercholesterolemia, beta-thalassemia, and sickle-cell disease, with the first base editing clinical readout occuring last December, when it was announced that Alyssa, a 13-year-old girl in the UK, was cleared of T-cell leukemia by receiving triply base-edited CAR-T cells. Liu graduated first in his class at Harvard College in 1994. During his doctoral research at UC Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his PhD in 1999 and became assistant professor of chemistry and chemical biology at Harvard University in the same year. He was promoted to associate professor in 2003 and to full professor in 2005. Liu became a Howard Hughes Medical Institute investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. In 2016 he became a Core Institute Member and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and Director of the Chemical Biology and Therapeutics Science Program. Liu has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. He is the 2022 King Faisal Prize Laureate in Medicine. He is the founder or co-founder of several biotechnology and therapeutics companies, including Prime Medicine, Beam Therapeutics, Editas Medicine, Pairwise Plants, Exo Therapeutics, Chroma Medicine, Resonance Medicine, and Nvelop Therapeutics. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
55. Future of Nanotechnology w/ Chad Mirkin - Professor @ Northwestern 43:43

منذ 2 years43:43

43:43

Chad Mirkin is the Director of the International Institute for Nanotechnology and the George B. Rathmann Prof. of Chemistry, Prof. of Chemical and Biological Engineering, Prof. of Biomedical Engineering, Prof. of Materials Science & Engineering, and Prof. of Medicine at Northwestern University. He is a chemist and a world-renowned nanoscience expert, who is known for his discovery and development of spherical nucleic acids (SNAs) and SNA-based biodetection and therapeutic schemes, the invention of Dip-Pen Nanolithography (DPN) and related cantilever-free nanopatterning methodologies, On-Wire Lithography (OWL), Co-Axial Lithography (COAL), and contributions to supramolecular chemistry and nanoparticle synthesis. He is the author of over 850 manuscripts and over 1,200 patent applications worldwide (over 400 issued), and the founder of multiple companies, including Nanosphere, AuraSense, TERA-print, Azul 3D, MattIQ, and Flashpoint Therapeutics. Mirkin has been recognized for his accomplishments with over 250 national and international awards. These include the King Faisal Prize in Science, the Faraday Medal, UNESCO-Equatorial Guinea International Prize for Research in Life Sciences, Kabiller Prize in Nanoscience and Nanomedicine, the SCI Perkin Medal, Friendship Award, Nano Research Award, AAAS Philip Hauge Abelson Award, Richards Award and Medal, Harrison Howe Award, the Remsen Award, Ralph N. Adams Award, the Dickson Prize in Science, the RUSNANOPRIZE, the Nichols Medal, the 2016 Dan David Prize, the inaugural NAS Sackler Prize in Convergence Research, the RSC Centenary Prize, the Friends of the National Library of Medicine Distinguished Medical Science Award, the 2014 National Security Science and Engineering Fellowship (NSSEFF) Award, the 2014 Thomson Reuters Highly Cited Researcher (2002-2012), the ACS Nano Lectureship Award for the Americas, the Vittorio deNora Award (The Electrochemical Society), the Linus Pauling Medal, the Thomson Reuters “Nobel-Class” Citation Laureate, RSC’s “Chemistry World” Entrepreneur of the Year Award, a Honorary Membership in the Materials Research Society of India, the Walston Chubb Award for Innovation, an Honorary Degree from Nanyang Technological Univ. Singapore, recognition as the Lee Kuan Yew Distinguished Visitor to Singapore, an Honorary Professorship from Hunan Univ. China, the ACS Award for Creative Invention, the Herman S. Bloch Award for Scientific Excellence in Industry, an Einstein Professorship of the Chinese Academy of Sciences, the Edward Mack Jr. Memorial Award, the $500,000 Lemelson-MIT Prize, the Havinga Medal, the Gustavus John Esselen Award, the Biomedical Eng. Society’s Distinguished Achievement Award, a DoD NSSEFF Award, the Pittsburgh Analytical Chemistry Award, the ACS Inorganic Nanoscience Award, the iCON Innovator of the Year Award, a NIH Director’s Pioneer Award, the Collegiate Inventors Award, an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State Univ. Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain’s Chicago Business “40 under 40 Award,” the Discover 2000 Award for Technological Innovation, I-Street Magazine’s Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the ACS Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the NSF Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Camille and Henry Dreyfus Foundation New Faculty Award. Mirkin served as a Member of the President’s Council of Advisors on Science & Technology (Obama Administration) for eight years, and he is one of very few scientists to be elected to all three US National Academies (Medicine, Science, and Engineering), and in addition, he is a Member of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors, the American Chemical Society, the American Institute for Medical and Biological Engineering, the Materials Research Society, and others. Mirkin has served on the Editorial Advisory Boards of over 30 scholarly journals, including JACS, Acc. Chem. Res., Angew. Chem., Adv. Mater., Biomacromolecules, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chem. Eur. J., Chemistry & Biology, Nanotechnology Law & Business, The Scientist, J. Mater. Chem., J. Cluster Sci., and Plasmonics. He is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co-edited multiple bestselling books. Mirkin holds a B.S. degree from Dickinson College (1986, elected into Phi Beta Kappa) and a Ph.D. degree in Chemistry from Penn. State Univ. (1989). He was an NSF Postdoctoral Fellow at MIT prior to becoming a professor at Northwestern Univ. in 1991. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
54. Foundations of Biotech w/ Harvey Lodish - Professor @ MIT / Founding Member @ Whitehead Institute 43:43

منذ 2 years43:43

43:43

Harvey Lodish is a Founding Member of the Whitehead Institute for Biomedical Research. He is a Professor of Biology and a Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT). He serves as a Member of the National Academy of Sciences and is an Associate (Foreign) Member of the European Molecular Biology Organization. He is also a Fellow of the American Association for the Advancement of Science, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the American Academy of Microbiology. As a member of the Board of Trustees of Boston Children’s Hospital, Professor Lodish chairs the Board of Trustees Research Committee. As the Founding Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center from 2008 to 2016, he oversaw the state’s $1 billion investments in the life sciences. Starting in 1973, his laboratory concentrated on the biogenesis, structure, and function of several important secreted and plasma membrane glycoproteins. To date, his group has made key discoveries in the fields of red blood cell development and therapeutics, long non-coding RNAs, and adipocyte biology. Most recently, his laboratory developed culture systems for generating mature human red blood cells from hematopoietic stem cells. He co-founded Rubius Therapeutics, a company that uses gene- and enzyme-modified red blood cells as vehicles for the long- term introduction of many novel therapeutics, immunomodulatory agents, and diagnostic imaging probes into the human body. Lodish has extensive experience in the biotechnology industry. He was a founding member (1980) and Principal of the consulting company BIA. He was a founder and scientific advisory board member of Genzyme, Inc. He was also a scientific founder of Arris (now Axys) Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc. In addition, he was formerly a scientific advisory board member of AstraZeneca, Genset SA, and Dyax Corporation. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
53. Future of Immunology w/ Jeff Bluestone - Professor Emeritus @ UCSF / Co-Founder & CEO @ Sonoma Biotherapeutics 43:43

منذ 2 years43:43

43:43

Jeff Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus at the Diabetes Center of The University of California, San Francisco. Bluestone is a highly accomplished scientific researcher and international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell costimulation to treat autoimmune disease and organ transplantation and the first FDA-approved CTLA-4 antagonist drugs for the treatment of metastatic melanoma. He was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes, psoriatic arthritis, and the reversal of kidney transplant rejection. In addition to his research, Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. He recently led the Parker Institute for Cancer Immunotherapy as president and CEO. He served as a member of the Blue Ribbon Panel, a board of scientific experts appointed by then Vice President Joe Biden to guide the NCI Cancer Moonshot Research Initiative. He was also the Ludwig Professor and director of the Ben May Institute at The University of Chicago and served as a senior investigator at the NCI. Bluestone holds a BS and an MS from Rutgers University and a PhD in immunology from the Weill Cornell Graduate School of Medical Sciences. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
52. AI & Patient Centricity in Pharma w/ Frank Nestle - Global Head of Research & CSO @ Sanofi 43:43

منذ 2 years43:43

43:43

Frank Nestle is global head of research and chief scientific officer at Sanofi, with responsibility for its main therapeutic research areas of immunology and inflammation, oncology, neurology, rare diseases, hematology, and genomic medicine. Before joining Sanofi in 2016, Nestle was a professor and chair of cutaneous medicine and immunotherapy at King’s College London and practiced medicine at Guy’s and St. Thomas’ Hospital. At King’s College, he led research, translational clinical trials, and teams in dermatology, allergology, and immunology. He also held several executive roles, in particular at the Guy’s and St Thomas’ Biomedical Research Center. Nestle is a fellow of the Academy of Medical Sciences, a senior investigator emeritus at the National Institute for Health Research, and past president of the Federation of Clinical Immunology Societies. He has published over 220 scientific articles and has received several awards and honors, including the Alfred Marchionini Research Award at the 20th World Congress of Dermatology. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
51. Future of SynBio w/ Jay Keasling - Professor @ Berkeley 43:43

منذ 3 years43:43

43:43

Jay Keasling is the Philomathia Professor of Alternative Energy at the University of California, Berkeley in the Departments of Bioengineering and Chemical and Biomolecular Engineering, senior faculty scientist at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute (JBEI). Dr. Keasling’s research focuses on the metabolic engineering of microorganisms for degradation of environmental contaminants or for environmentally friendly synthesis of drugs, chemicals, and fuels. Keasling received a B.S. in Chemistry and Biology from the University of Nebraska and M.S. and Ph.D. in Chemical Engineering from the University of Michigan, and did post-doctoral research in biochemistry at Stanford University. He is a member of the National Academy of Engineering and the National Academy of Inventors. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
50. Pioneering Bioorthogonal Chemistry w/ Carolyn Bertozzi - Professor @ Stanford & 2022 Nobel Laureate 43:43

منذ 3 years43:43

43:43

Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology (by courtesy) at Stanford University, the Baker Family Director at Sarafan ChEM-H, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University as an Institute Scholar at Sarafan ChEM-H. Bertozzi's research interests span the disciplines of chemistry and biology. She invented the concept of “bioorthogonal chemistry” and has widely applied such reactions to study biological processes and build new types of molecular therapeutics. As well, her lab studies the roles of cell surface glycosylation in human health and disease. Her lab focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and exploiting this information for development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. She is an elected member of the National Academy of Sciences, the National Academy of Medicine, and the German Academy of Sciences Leopoldina, and she is a Foriegn Fellow of the Royal Society, UK. Her efforts in undergraduate education have earned her the UC Berkeley Distinguished Teaching Award and the Donald Sterling Noyce Prize for Excellence in Undergraduate Teaching. Some awards of note include the Lemelson-MIT award for inventors, Ernst Schering Prize, MacArthur Foundation Fellowship, the ACS Award in Pure Chemistry, and just last week, the 2022 Nobel Prize in Chemistry. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
49. Engineering Precision Medicine w/ Joel Dudley - Partner @ Innovation Endeavors / Former CSO @ Tempus 43:43

منذ 3 years43:43

43:43

Joel Dudley is a Partner @ Innovation Endeavors and an experienced leader, medical professional, researcher, and entrepreneur. Joel previously served as the Chief Scientific Officer at Tempus, a company focused on bringing the power of data and artificial intelligence to healthcare. Before joining Tempus, Joel was an Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the Mount Sinai Health System. Prior to joining Innovation Endeavors, Joel co-founded Onegevity Health (acquired by Thorne), a company developing health intelligence platforms for preventative health, and NuMedii, a company developing machine learning and A.I. approaches for drug discovery. Joel has published 200+ peer-reviewed research papers that have been referenced and featured in the New York Times, Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets. Joel earned a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from Stanford University School of Medicine. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
48. Future of Precision Health w/ Carlos Bustamante - Professor @ Stanford / Co-Founder & CEO @ Galatea 43:43

منذ 3 years43:43

43:43

Carlos Bustamante, over the past 15 years, has led a multidisciplinary team working on problems at the interface of computational and biological sciences. Much of his research has focused on genomics technology and its application in medicine, agriculture, and evolutionary biology. His first academic appointment was at Cornell University's College of Agriculture and Life Sciences. There, much of his work focused on population genetics and agricultural genomics motivated by a desire to improve the foods we eat and the lives of the animals upon which we depend. He moved to Stanford in 2010, to focus on enabling clinical and medical genomics on a global scale. He has been particularly focused on reducing health disparities in genomics by: (1) calling attention to the problem raised by >95% of participants in large-scale studies being of European descent; and (2) broadening representation of understudied groups, particularly U.S. minority populations and those from Latin America. Taken together, this work has empowered decision-makers to utilize genomics and data science in the service of improving human health and wellbeing. As Inaugural Chair of Stanford's new Department of Biomedical Data Science, his future goal is to scale these operations from focusing on researchers to consumers and patients, where we ultimately want our work to have the greatest impact. In 2017, Bustamante was appointed a Chan-Zuckerberg Investigator and, from 2011–2016, he was a MacArthur Fellow. He also received a Stanford Prize in Population Genetics and Society in 2016, a Sloan Research-Fellowship in Molecular Biology from 2007–2009, and a Marshall-Sherfield Fellowship from 2001–2002. Bustamante also has a strong interest in building new academic units, non-profits, and companies. He is Founding Director (with Marcus Feldman) of the Stanford Center for Computational, Evolutionary, and Human Genomics (CEHG), and former Founding Associate Director of the Cornell Center for Comparative and Population Genomics (3CPG). He serves as an advisor to the US federal government, private companies, startups, and non-profits in the areas of computational genomics, population and medical genetics, and veterinary and plant genomics. He is currently Director of EdenRoc Sciences, Founder @ Arc Bio, & an SAB member of: Embark Veterinary, the Mars/IBM Food Safety Board, & Digitalis Ventures. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
47. Taking Agency of Your Care (& Your Company) w/ Lee Cooper - Senior Director of Venture Investments @ Leaps by Bayer 43:43

منذ 3 years43:43

43:43

Lee Cooper is Senior Director of Venture Investments @ Leaps by Bayer, where he aims to contribute to new biotechnologies that enable patients and communities to live healthier lives. Lee is on the faculty of Dartmouth’s Thayer School of Engineering and teaches “The Ecosystem for Bio-Innovation.” Prior to joining Leaps, Lee was Entrepreneur-in-Residence with RA Capital and founder of Enlight Bio, a biotech focused on genetic disease. Previously, Lee worked in corporate development for Moderna Therapeutics, leading and supporting transactions, financings, and partnerships to develop novel therapeutics and vaccines. Lee serves on the Boards of multiple therapeutic platform-focused biotech companies. He is the founder of the Institute for Genetic Disease Prevention and has written on innovation and ethics for Wired, Slate, Neo.Life, and STAT News. Lee earned his J.D. and M.B.A. from Columbia University, and graduated from Dartmouth College with an A.B. in Religion and Public Policy. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
46. Building Innovation Institutes w/ Patrick Hsu - Co-Founder @ Arc Institute / Assistant Professor @ UC Berkeley 43:43

منذ 3 years43:43

43:43

Patrick Hsu is an Assistant Professor of Bioengineering at the University of California, Berkeley, and is a co-founder and core investigator at the Arc Institute. He is a pioneer of CRISPR technology. In his Lab at Berkeley, Patrick seeks to improve our understanding and ability to control genetic circuits for the advancement of human health. His academic work has been featured in multiple prestigious awards, including Forbes’ 30 Under 30, the NIH Early Independence Award, and the MIT Technology Review’s Innovators Under 35 to name a few. Patrick co-founded Arc to advance our understanding of the root causes of complex diseases. Arc seeks to accelerate discovery by enabling the impactful, potentially risky, long-term, moonshot projects through financial and operational enablement. Without the systemic pressure to constantly write grants, Arc aims to unlock the full potential of the brilliant minds of our country’s top scientists. Patrick holds a PhD in Biochemistry and Biological Engineering from Harvard, an A.M. in Biology from Harvard, and a B.S. in Molecular & Cell Biology from the University of California, Berkeley. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
45. Translational Medicine & Public Health w/ David Kaufman - Partner @ Third Rock Ventures 43:43

منذ 3 years43:43

43:43

David Kaufman is a Partner @ Third Rock Ventures. Before joining TRV, he was Chief Medical Officer and head of translational development at the Bill and Melinda Gates Medical Research Institute (MRI). He helped establish the Gates MRI as a "nonprofit biotech," developing novel drugs and vaccines for tuberculosis, malaria, enteric diseases, neonatal health, and other global health challenges. Prior to that, Kaufman led translational oncology at Merck Research Laboratories, where he oversaw immuno-oncology translational medicine, novel biomarker development and global translational research partnering. He joined Merck through the Merck Drug Development and Leadership Program, and worked across vaccines, infectious diseases and clinical oncology. Before joining Merck, he was a physician in the Division of Infectious Diseases and the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and an instructor in medicine at Harvard Medical School. Kaufman received his M.D. from Cornell University School of Medicine and his Ph.D. in immunology and molecular virology from The Rockefeller University. He trained in internal medicine at the University of California, San Francisco, and in infectious diseases at Massachusetts General Hospital and Brigham and Women’s Hospital. He is a member of the board of directors of Hookipa Pharma and a director ex officio of the Society for the Immunotherapy of Cancer (SITC). Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
44. Design Thinking in Biotech w/ Chris Garabedian - CEO @ Xontogeny / Former CEO @ Sarepta 43:43

منذ 3 years43:43

43:43

Chris Garabedian is the Chairman & CEO of Xontogeny where he supports companies with cutting-edge technologies from early development through clinical proof of concept. Chris has decades of leadership experience in the biopharmaceutical industry. From 2011 to 2015, Chris led the turnaround of Sarepta Therapeutics as CEO. Prior to that, Chris served as VP of Corporate Strategy at Celgene and has held multiple executive roles at Gilead across corporate development, marketing, and medical affairs. Chris started his career in the biopharmaceutical industry as a consultant and holds a BS in Marketing from the University of Maryland. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
43. Future of Genetic Medicine w/ Scribe Therapeutics Founders - Ben Oakes & Dave Savage 43:43

منذ 3 years43:43

43:43

Ben Oakes is Co-founder, President, & CEO @ Scribe Therapeutics. He has contributed to over 25 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. A previous Innovative Genomics Institute Entrepreneurial Fellow, Ben has been named to the San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in biopharma, Business Insider 30 Under 40 transforming healthcare, and the Biocom Life Sciences Catalyst Awards. He received a PhD in Molecular and Cellular Biology from the University of California, Berkeley, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Dave Savage is Co-founder & Scientific Advisor @ Scribe Therapeutics. He is an Associate Professor of Biochemistry, Biophysics, and Structural Biology at the University of California, Berkeley and in 2021 was selected as an Investigator of the Howard Hughes Medical Institute. Dave is an expert in biochemistry and protein engineering, and his laboratory develops novel tools for studying and manipulating the genome. Previously, he was a Department of Energy Physical Biosciences Fellow of the Life Sciences Research Foundation at Harvard Medical School. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
42. Pharma BD to TechBio VC w/ Becky Pferdehirt - Partner @ Andreessen Horowitz (a16z Bio + Health Fund) & Seth Lieblich - Principal @ 8VC (Bio Team) 43:43

منذ 3 years43:43

43:43

Becky Pferdehirt is a Partner on the a16z bio investing team. She focuses on early stage companies building technology platforms for therapeutic discovery and development. Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation. Becky completed her postdoctoral education at Genentech studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT. & Seth Lieblich is a Principal on the 8VC Bio Team. Seth came from Amgen where he was in Amgen Business Development’s technology group where he was responsible for search & evaluation and transactions for platform technologies across a number of therapeutic and functional areas. Seth was also responsible for strategic academic partnerships across all therapeutic and geographic areas. Prior to Amgen, Seth was at ZS Associates where he led teams engaging in market research, sales force design, and strategy. Prior to ZS Associates, Seth was co-founder and COO of Protomer Technologies, a Pasadena-based biologics startup. Seth received his Ph.D. in Biochemistry and Molecular Biophysics from the California Institute of Technology and holds a B.S and M.S. in Biochemistry from Brandeis University. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
41. Cell Free Systems w/ Michael Jewett - Professor @ Northwestern / Director @ NU Center for Synthetic Biology 43:43

منذ 3 years43:43

43:43

Michael Jewett is the Charles Deering McCormick Professor of Teaching Excellence, a Professor of Chemical & Biological Engineering, & Co-Director of the Center for Synthetic Biology @ Northwestern University. He is also an Institute Fellow at the Northwestern Argonne Institute for Science & Engineering. Jewett’s lab seeks to re-conceptualize the way we engineer complex biological systems for compelling applications in medicine, materials, and energy by transforming biochemical engineering with synthetic biology. Dr. Jewett is the recipient of the NIH Pathway to Independence Award in 2009, David and Lucile Packard Fellowship in Science and Engineering in 2011, the DARPA Young Faculty Award in 2011, the Agilent Early Career Professor Award in 2011, the 3M non-tenured faculty grant in 2012, the Camille-Dreyfus Teacher-Scholar Award in 2015, the ACS Biochemical Technologies Division Young Investigator Award in 2017, and the Biochemical Engineering Journal Young Investigator Award in 2018. w/ Special Guest Host: David Mace David Mace is Co-founder & CEO @ SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge. Previously David was an Entrepreneur in Residence at 8VC, where he focused on the intersection of biology & computer science. He is a graduate of the California Institute of Technology. SwiftScale Biologics ( @SwiftScaleBio ) seeks to bring life-saving drugs to patients faster than previously possible. Specifically, SwiftScale uses cutting-edge cell-free and bacterial production platforms to rapidly produce protein therapeutics. SwiftScale’s technology is faster and cheaper than traditional manufacturing approaches, reducing time and cost to reach clinical trials and market. In Dec 2021, National Resilience acquired SwiftScale. Resilience is a technology focused manufacturing company dedicated to broadening access to complex medicines. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
40. TechBio Era w/ Vik Bajaj - Managing Director @ Foresite Capital 43:43

منذ 3 years43:43

43:43

Vik Bajaj is a Managing Director @ Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare. Prior to joining Foresite Capital, Vik was the chief scientific officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the co-founder and former chief scientific officer of Verily (formerly Google Life Sciences) and served as chair of its Scientific Advisory Board. A former academic principal investigator, Vik retains appointments as associate professor (consulting) at the Stanford School of Medicine, and as an affiliate scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology. Vik’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. He and his collaborators have developed nanotechnology probes for the early detection and molecular imaging of disease, spectroscopic tools for imaging objects on the nanoscale, microfabricated and miniaturized analytical and imaging systems for point-of-care testing, methods and devices that dramatically enhance the sensitivity and specificity of MRI, and new tools for clinical bioinformatics and integrative systems biology. Aspects of this work have been commercialized through several startups. At GRAIL, Vik led laboratory and data science teams at the forefront of industrial cancer genomics and diagnostics development. He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
39. Future of Drug Delivery w/ Samir Mitragotri - Professor @ Harvard / Core Faculty @ Wyss Institute 43:43

منذ 3 years43:43

43:43

Samir Mitragotri is the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering. Samir is an elected member of the National Academies of Engineering and Medicine, and elected fellow of the American Institute of Medical and Biological Engineering, the American Association for the Advancement of Science, the National Academy of Inventors, the Controlled Release Society, the Biomedical Engineering Society, and the American Association of Pharmaceutical Scientists. He is a Thomson Reuters Highly Cited Researcher. He serves on the editorial boards of several journals and currently serves as the founding Editor-in-Chief of Bioengineering and Translational Medicine. Samir has made groundbreaking contributions to the field of biological barriers and drug delivery systems. His research, which is focused on the fundamental understanding of biological barriers, has led to the development of new materials and technologies for diagnosis and treatment of various ailments including diabetes, cancer, cardiovascular diseases, skin conditions and infections. Many of his technologies have advanced to human clinical studies and products. Samir’s key technical contributions include the development of novel transdermal and oral delivery systems. Specifically in transdermal drug delivery, Samir has established a fundamental knowledgebase of transport properties of skin and has pioneered numerous technologies including low-frequency ultrasound, pulsed microjet injector, high throughput screening (INSIGHT), in situ hydrogels and ionic liquids for transdermal drug delivery. He has also developed ionic liquid-based technologies for oral delivery of insulin, monoclonal antibodies and other biologics. Samir has also developed unique bio-inspired nanoparticles that hitchhike on circulatory cells to avoid immune clearance and allow targeted delivery to tissues. Samir is the author of more than 400 publications in the area of drug delivery and biomaterials, has given close to 500 invited and contributed presentations worldwide, and is an inventor on more than 200 pending or issued patents. He is a co-founder of several companies that are developing therapeutic or diagnostic products based on his inventions. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
38. Future of Organoids w/ Hans Clevers - Organoid Pioneer & Professor @ Hubrecht Institute 43:43

منذ 3 years43:43

43:43

Hans Clevers is Director & Professor of Molecular Genetics @ the Hubrecht Institute in the Netherlands. He is also University Professor at the University Utrecht and Oncode Investigator. Clevers is one of the world’s leading researchers on stem cells and their potential for regenerative therapy. Over the past decade, his lab has produced vital studies on stem cells and the nature of self-renewal pathways controlling stem cells. Clevers was the first researcher to demonstrate the existence of long-lived stem cells in many tissues, including the intestine and stomach. Starting from the discovery that the TCF gene is the transcriptional endpoint of the WNT pathway, a pathway that is implicated in stem cell control, Clevers demonstrated that one of the TCF genes is essential for the stem cell compartment in the intestine. w/ Special Guest Host: Xiling Shen - Co-Founder & CEO @ Xilis Xiling Shen is Co-Founder & CEO @ Xilis. Before Xilis, Shen was the Hawkins Family Associate Professor at Duke University. Shen’s research interests lie in precision medicine and systems biology. His lab integrates engineering, computational and biological techniques to study cancer, stem cells, microbiota and the nervous system in the gut. This multidisciplinary work has been instrumental in initiating several translational clinical trials in precision therapy. He is the director of the Woo Center for Big Data and Precision Health (DAP) and a core member of the Center for Genomics and Computational Biology (GCB). Hans Clevers & Xiling Shen are Co-Founders @ Xilis. Xilis is developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and supports drug discovery and development for pharmaceutical companies. Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up development and clinical trials of cancer drugs by enabling analysis of authentic tumor microenvironments, high-throughput preclinical modeling, and clinical patient selection capabilities. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
37. Biophysics & Rejuvenation w/ Stephen Quake - Professor @ Stanford / Co-President @ Chan Zuckerberg Biohub 43:43

منذ 3 years43:43

43:43

Stephen Quake is the Lee Otterson Professor of Bioengineering & Professor of Applied Physics @ Stanford University & Co-President of the Chan Zuckerberg Biohub. Quake has invented many measurement tools for biology, including new DNA sequencing technologies that have enabled rapid analysis of the human genome and microfluidic automation that allows scientists to efficiently isolate individual cells and decipher their genetic code. Quake is also well known for inventing new diagnostic tools, including the first non-invasive prenatal test for Down syndrome and other aneuploidies. His test is rapidly replacing risky invasive approaches such as amniocentesis, and millions of women each year now benefit from this approach. His innovations have helped to radically accelerate the pace of biology and have made medicine safer by replacing invasive biopsies with simple blood tests. Quake was elected a member of the National Academy of Engineering in 2013 for achievements in single-cell analysis and large-scale integration of microfluidic devices. He has also been elected to the National Academy of Sciences, the Institute of Medicine, the American Physical Society, the American Institute for Medical and Biological Engineering and the American Academy of Arts and Sciences. He is the recipient of numerous international awards, including the Human Frontiers of Science Nakasone Prize, the Jacob Heskel Gabbay Award, the MIT-Lemelson Prize for Innovation, the Raymond and Beverly Sackler International Prize in Biophysics, the NIH Director’s Pioneer Award, the American Society of Microbiology’s Promega Biotechnology Award, and the Royal Society of Chemistry Publishing’s Pioneer of Miniaturization Award. He has founded or co-founded several companies, including Fluidigm, Helicos Biosciences, Verinata Health, Quanticel Pharmaceuticals, Moleculo, Cellular Research, Immumetrix, and Karius. Quake received a B.S. in Physics and M.S. in Mathematics from Stanford University in 1991 and a doctorate in Theoretical Physics from the University of Oxford in 1994 as a Marshall Scholar. He did his postdoctoral work at Stanford in single molecule biophysics with Steven Chu. Quake joined the faculty of the California Institute of Technology at the age of 26, where he rose through the ranks and was ultimately appointed the Thomas and Doris Everhart Professor of Applied Physics and Physics. From 2006 to 2016 he was an Investigator of the Howard Hughes Medical Institute. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
36. Building Biotech Ecosystems w/ John Flavin - Founder & CEO @ Portal Innovations 43:43

منذ 3 years43:43

43:43

John Flavin is Founder & CEO @ Portal Innovations, a premier venture development engine that builds and invests in early stage life sciences ventures. Portal’s differentiated mix of crafted capital drives companies from scientific ideation to business creation, helping entrepreneurs translate cutting-edge technology into sustainable, global businesses with breakthrough products to help patients. Prior to launching Portal, John founded and built several life sciences companies including Pyxis Oncology (NASDAQ: PYXS) and civic incubators MATTER and the Polsky Center for Entrepreneurship and Innovation at the University of Chicago, a first-of-its-kind, fully integrated academic value creation engine which translates innovation through the launch of new businesses and partnerships at the University of Chicago, 2 national laboratories and Chicago’s South Side by providing entrepreneurship education, incubation space, IP licensing and capital. John has completed numerous public and private capital financings totaling over $365 million including 3 NASDAQ IPOs and has raised over $135 million in philanthropic and corporate funding to support university technology commercialization and venture start-up activities. He possesses a deep understanding of academic-to-commercial innovation ecosystem development with a particular focus on the life sciences sector and has established key relationships with a diverse set of prospective partners representing all elements of the life sciences community including corporate, venture capital and academic stakeholders. John is a frequent key-note speaker, panelist and lecturer on the topics of innovation, entrepreneurship and commercialization and is quoted often in the financial press including Wall Street Journal, Chicago Tribune, Crain’s Chicago Business and thought leadership media appearances on Bloomberg, WGN, and WTTW Chicago Tonight. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
35. Accelerating Diagnostic Innovation w/ David Walt - Professor @ Harvard / Core Faculty @ Wyss Institute 43:43

منذ 3 years43:43

43:43

David Walt is the Hansjörg Wyss Professor of Bioinspired Engineering @ Harvard Medical School, Professor of Pathology @ Harvard Medical School & Brigham and Women’s Hospital, Core Faculty Member of the Wyss Institute @ Harvard University, Associate Member @ the Broad Institute, Howard Hughes Medical Institute Professor, & is co-Director of the Mass General Brigham Center for COVID Innovation. Walt pioneered the use of microwell arrays for single-molecule detection and genetic measurements, which has revolutionized the process of genetic and proteomic analysis, enabling the cost of DNA sequencing and genotyping to plummet nearly a millionfold in the last decade. Walt is the Scientific Founder of Illumina, Quanterix, and has co-founded multiple other life sciences startups including Ultivue, Arbor Biotechnologies, Sherlock Biosciences, Vizgen, and Torus Biosciences. His lab develops new diagnostics tools and new biomarker assay technologies based on single molecule detection that can address unmet clinical needs in diagnostics. The lab is focused on early detection of breast cancer, detection of active tuberculosis and other infectious diseases, and diagnosis of neurodegenerative diseases, His lab has also been deeply involved in developing new tools to understand and diagnose COVID-19. Walt’s lab also pursues fundamental research on single enzyme molecules to provide insight into enzyme mechanisms. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules including the 2021 Kabiller Prize in Nanoscience and Nanomedicine. He is a member of the U.S. National Academy of Engineering, the U.S. National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the American Association for the Advancement of Science, a Fellow of the National Academy of Inventors, and is inducted in the US National Inventors Hall of Fame. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

BIOS

1
34. Biologically Inspired Engineering w/ Don Ingber - Founding Director @ Wyss Institute / Professor @ Harvard 43:43

منذ 3 years43:43

43:43

Don Ingber is the Founding Director of the Wyss Institute for Biologically Inspired Engineering @ Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University. Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads scientific and engineering teams that cross a broad range of disciplines to develop breakthrough bio-inspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, cell structure, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Prof. Ingber also has helped to break down boundaries between science, art and design. Ingber has authored more than 500 publications and almost 200 patents, founded 7 companies, and has presented over 550 plenary presentations and invited lectures world-wide. He is a member of the National Academy of Engineering, National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. Prof. Ingber has been the scientific founder of seven companies: Neomorphics, Tensegra, Boa Biomedical, FreeFlow Medical Devices, Unravel Bio, StataDx, and Emulate. Thank you for listening! BIOS ( @BIOS_Community ) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures ( @AlixVentures ) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod ( link & license )…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.